Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 18/20 | 0.49 |
| ▸ | HCRTR1 | O43613 | 15/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | AGER | Q15109 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MYC | P01106 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL264270 | 0.98 | HCRTR2 (0.50) | HCRTR2HCRTR1KDM4EALDH1A1CYP3A4 | |
| SCHEMBL30775045 | 0.98 | HCRTR2 (0.50) | HCRTR2HCRTR1KDM4EALDH1A1CYP3A4 | |
| SCHEMBL607037 | 0.97 | HCRTR2 (0.49) | HCRTR2HCRTR1KDM4EALDH1A1CYP3A4 | |
| SCHEMBL31336716 | 0.87 | HCRTR2 (0.42) | HCRTR2HCRTR1KDM4EALDH1A1CYP3A4 | |
| SCHEMBL31372446 | 0.87 | HCRTR2 (0.41) | HCRTR2HCRTR1KDM4EALDH1A1MAPT | |
| SCHEMBL3385656 | 0.87 | HCRTR2 (0.41) | HCRTR2HCRTR1KDM4EALDH1A1MAPT | |
| SCHEMBL19151517 | 0.85 | HCRTR2 (0.50) | HCRTR2HCRTR1 | |
| SCHEMBL2471955 | 0.83 | HCRTR2 (0.42) | HCRTR2HCRTR1KDM4EALDH1A1CYP3A4 | |
| SCHEMBL30775053 | 0.83 | HCRTR2 (0.42) | HCRTR2HCRTR1KDM4EALDH1A1CYP3A4 | |
| SCHEMBL3389125 | 0.83 | KDM4E (0.49) | HCRTR2HCRTR1KDM4EALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012089607-A1 | NOVEL COMPOUNDS WITH A 3A-AZABICYCLO [4.1.0] HEPTANE CORE ACTING ON OREXIN RECEPTORS | GLAXO GROUP LIMITED (GB) | 2012-07-05 | — | — | WO | disclosed |
| EP-2421850-A1 | 3 -AZABICYCLO [4.1.0]HEPTANES USED AS OREXIN ANTAGONISTS | Glaxo Group Limited (GB) | 2012-02-29 | — | — | EP | disclosed |
| US-20120040991-A1 | 3-AZABICYCLO [4.1.0] HEPTANES USED AS OREXIN ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| EP-2379550-A1 | PIPERIDINE DERIVATIVES USEFUL AS OREXIN ANTAGONISTS | Glaxo Group Limited (GB) | 2011-10-26 | — | — | EP | disclosed |
| US-20110257198-A1 | PIPERIDINE DERIVATIVES USEFUL AS OREXIN ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2011-10-20 | — | — | US | disclosed |
| WO-2010122151-A1 | 3 -AZABICYCLO [4.1.0] HEPTANES USED AS OREXIN ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010072722-A1 | PIPERIDINE DERIVATIVES USEFUL AS OREXIN ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2010-07-01 | — | — | WO | disclosed |
| US-20100144760-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257198-A1 | PIPERIDINE DERIVATIVES USEFUL AS OREXIN ANTAGONISTS | HCRTR2, HCRTR1, VIPR2 | HCRTR2 1/4885HCRTR1 2/4885KDM4E 1459/4885 |
| US-20100144760-A1 | NOVEL COMPOUNDS | HTR3B, HTR1B, HTR2B | HCRTR2 1425/4885HCRTR1 2016/4885KDM4E 1224/4885 |
| US-20120040991-A1 | 3-AZABICYCLO [4.1.0] HEPTANES USED AS OREXIN ANTAGONISTS | HCRTR2, HCRTR1, NPY2R | HCRTR2 1/4885HCRTR1 2/4885KDM4E 1115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.